Literature DB >> 8127897

Direct demonstration of three different states of the pancreatic cholecystokinin receptor.

V D Talkad1, K P Fortune, D A Pollo, G N Shah, S A Wank, J D Gardner.   

Abstract

We used rat pancreatic acini as well as COS-7 cells transfected with the cloned pancreatic cholecystokinin (CCK) receptor and measured the abilities of CCK octapeptide (CCK-8) and L-364,718 (a CCK receptor antagonist) to inhibit binding of 125I-labeled CCK-8 (125I-CCK-8) and [3H]L-364,718. With pancreatic acini 125I-CCK-8 bound to two different states of the CCK receptor. The high-affinity state (1% of the receptors) had a Kd for CCK-8 of 985 pM and the low-affinity state (19% of the receptors) had a Kd for CCK-8 of 30 nM. [3H]L-364,718 bound to low-affinity receptors and to a previously unrecognized very-low-affinity state (80% of the receptors) having a Kd for CCK-8 of 13 microM. L-364,718 had the same affinity (Kd 3 nM) for each of the three different states of the CCK receptor. Similar measurements using transfected COS cells also identified three different states of the CCK receptor, with the very-low-affinity state being the most abundant. Thus, the ability of the CCK receptor to exist in three different states is an intrinsic property of the CCK receptor molecule itself.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8127897      PMCID: PMC43265          DOI: 10.1073/pnas.91.5.1868

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  Characterization of H2 histamine receptor: linkage to both adenylate cyclase and [Ca2+]i signaling systems.

Authors:  J Delvalle; L Wang; I Gantz; T Yamada
Journal:  Am J Physiol       Date:  1992-12

2.  Brain and gastrointestinal cholecystokinin receptor family: structure and functional expression.

Authors:  S A Wank; J R Pisegna; A de Weerth
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-15       Impact factor: 11.205

3.  Down-regulation and recycling of high affinity cholecystokinin receptors on pancreatic acinar cells.

Authors:  D Menozzi; R Vinayek; R T Jensen; J D Gardner
Journal:  J Biol Chem       Date:  1991-06-05       Impact factor: 5.157

4.  A new CCK analogue differentiates two functionally distinct CCK receptors in rat and mouse pancreatic acini.

Authors:  T Matozaki; J Martinez; J A Williams
Journal:  Am J Physiol       Date:  1989-10

5.  Somatostatin 28 interacts with CCK receptor in brain and pancreas.

Authors:  N Tahiri-Jouti; M Dufresne; N Viguerie; D Fourmy; J P Estève; J Rivier; L Moroder; C Susini; N Vaysse
Journal:  Neuropeptides       Date:  1991-06       Impact factor: 3.286

6.  C-terminal peptides of calcitonin gene-related peptide act as agonists at the cholecystokinin receptor.

Authors:  P N Maton; T Pradhan; S Moore
Journal:  Peptides       Date:  1990 Nov-Dec       Impact factor: 3.750

7.  Molecular cloning of a gene encoding the histamine H2 receptor.

Authors:  I Gantz; M Schäffer; J DelValle; C Logsdon; V Campbell; M Uhler; T Yamada
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-15       Impact factor: 11.205

8.  Cibacron blue-induced enhancement of agonist binding to cholecystokinin (CCK) receptors in solubilized pancreatic membranes.

Authors:  D S Yuan; S A Wank; J D Gardner
Journal:  Biochim Biophys Acta       Date:  1993-02-23

9.  Pancreatic receptors for cholecystokinin: evidence for three receptor classes.

Authors:  D H Yu; S C Huang; S A Wank; S Mantey; J D Gardner; R T Jensen
Journal:  Am J Physiol       Date:  1990-01

10.  Purification, molecular cloning, and functional expression of the cholecystokinin receptor from rat pancreas.

Authors:  S A Wank; R Harkins; R T Jensen; H Shapira; A de Weerth; T Slattery
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

View more
  7 in total

1.  Pharmacological evidence for putative CCK(1) receptor heterogeneity in human colon smooth muscle.

Authors:  M F Morton; E A Harper; I A Tavares; N P Shankley
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

2.  Arginine 197 of the cholecystokinin-A receptor binding site interacts with the sulfate of the peptide agonist cholecystokinin.

Authors:  V Gigoux; B Maigret; C Escrieut; S Silvente-Poirot; M Bouisson; J A Fehrentz; L Moroder; D Gully; J Martinez; N Vaysse; A D Fourmy
Journal:  Protein Sci       Date:  1999-11       Impact factor: 6.725

Review 3.  Cholecystokinin receptors.

Authors:  P Boden; M D Hall; J Hughes
Journal:  Cell Mol Neurobiol       Date:  1995-10       Impact factor: 5.046

4.  Characterization and distribution of binding sites for a new neurotensin receptor antagonist ligand, [3H]SR 48692, in the guinea pig brain.

Authors:  C Betancur; M Canton; D Gully; G Vela; D Pélaprat; W Rostène
Journal:  J Pharmacol Exp Ther       Date:  1995-06       Impact factor: 4.030

5.  Modulation of cholecystokinin activity by albumin.

Authors:  S C Huang; V D Talkad; K P Fortune; S Jonnalagadda; C Severi; G Delle Fave; J D Gardner
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

6.  Synthesis and in vitro characterization of radioiodinatable benzodiazepines selective for type 1 and type 2 cholecystokinin receptors.

Authors:  Eyup Akgün; Meike Körner; Fan Gao; Kaleeckal G Harikumar; Beatrice Waser; Jean Claude Reubi; Philip S Portoghese; Laurence J Miller
Journal:  J Med Chem       Date:  2009-04-09       Impact factor: 7.446

7.  Cholecystokinin and psychiatric disorders : role in aetiology and potential of receptor antagonists in therapy.

Authors:  J Shlik; E Vasar; J Bradwejn
Journal:  CNS Drugs       Date:  1997-08       Impact factor: 5.749

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.